UNICREDIT BANK/CALL/VERTEX PHARMACEUTICALS/550/0.1/15.01.25 Stock UNICREDIT BANK/CALL/VERTEX PHARMACEUTICALS/550/0.1/15.01.25
Add to a list
To use this feature you must be a member
Log inSign up

UNICREDIT BANK/CALL/VERTEX PHARMACEUTICALS/550/0.1/15.01.25 Share Price

Warrant

DE000HC620S7

Real-time BOERSE MUENCHEN 01:11:12 06/06/2024 pm IST
2.31 EUR 0.00% Intraday chart for UNICREDIT BANK/CALL/VERTEX PHARMACEUTICALS/550/0.1/15.01.25
Current month+60.42%
1 month+272.58%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes
Chart VERTEX PHARMACEUTICALS INCORPORATED
Chart UNICREDIT BANK/CALL/VERTEX PHARMACEUTICALS/550/0.1/15.01.25

Latest news about VERTEX PHARMACEUTICALS INCORPORATED

Vertex Pharmaceuticals Insider Sold Shares Worth $1,495,000, According to a Recent SEC Filing MT
Vertex Pharmaceuticals Insider Sold Shares Worth $1,000,500, According to a Recent SEC Filing MT
Vertex Pharmaceuticals Incorporated : 2024 VRTX William Blair Growth Stock Conference Presentation vFinal PU
Transcript : Vertex Pharmaceuticals Incorporated Presents at The 44th Annual William Blair Growth Stock Conference, Jun-04-2024 04:00 PM
More news

Quotes 5-day view

Date Price Change
06/24/06 2.31 0.00%
05/24/05 2.31 +17.26%
04/24/04 1.97 +15.88%
03/24/03 1.7 +18.06%
31/24/31 1.44 +21.01%

Real-time BOERSE MUENCHEN

Last update June 06, 2024 at 01:11 pm IST

More quotes

Static data

Product typeWarrants
Buy / SellCALL
Underlying VERTEX PHARMACEUTICALS INCORPORATED
IssuerLogo Issuer UniCredit UniCredit
WKN HC620S
ISINDE000HC620S7
Date issued 14/04/2023
Strike 550 $
Maturity 15/01/2025 (224 Days)
Parity 10 : 1
Emission price 1.53 €
Emission volume N/A
Settlement règlement en espèces
Currency EUR

Technical Indicators

Highest since issue 2.75 €
Lowest since issue 0.53 €
Delta0.38x
Omega 7.261
Premium19.04x
Gearing19.31x
Moneyness 0.8783
Difference Strike 66.96 $
Difference Strike %+12.17%
Spread 0.2 €
Spread %8.33%
Theoretical value 2.300
Implied Volatility 28.67 %
Total Loss Probability 70.53 %
Intrinsic value 0.000000
Present value 2.300
Break even 575.02 €
Theta-0.07x
Vega0.13x
Rho0.09x

Company Profile

Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases. Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
More about the company

Ratings for Vertex Pharmaceuticals Incorporated

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Consensus: Vertex Pharmaceuticals Incorporated

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
483 USD
Average target price
463.5 USD
Spread / Average Target
-4.04%
Consensus
  1. Stock Market
  2. Warrants
  3. Warrant